Merck KGaA agrees to acquire Silence Therapeutics for $20 per ADS

By Public Technologies
  • Merck KGaA agreed to acquire Silence Therapeutics for approximately $1.3 billion in equity value, with an enterprise value of $1.1 billion.
  • Shareholders will receive $20 cash per American Depositary Share, representing three ordinary shares, or $6.6667 per ordinary share.
  • The offer represents a 130% premium to the October 16, 2026, closing price and 82% above the $10.99 30-day volume-weighted average.
  • Completion is expected in the first quarter of 2027, subject to shareholder and court approval, regulatory clearances and customary closing conditions.
  • The acquisition will expand Merck's specialty and rare-disease pipeline, adding Divesiran, a polycythemia vera treatment candidate being advanced toward Phase 3 development.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silence Therapeutics plc published the original content used to generate this news brief via Business Wire (Ref. ID: 20261019615040) on October 19, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.